RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing RNAi-based immunotherapies to treat cancer, today announced that it received a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE